AIST
Acute Ischemic Stroke Trial - Oral Aspirin vs Intravenous Heparin on Stroke Progression
|
Status:
Enrollment completed November of 2001. An article is being prepared for publication.
Purpose:
To compare the effects of intravenous heparin with those of oral aspirin on acute ischemic stroke progression.
Year Started:
1999
Year Finished:
2002
Design:
Multi-center, prospective, single-blinded, randomized, controlled study.
Inclusion Criteria
Patients who presented within 48 hours of ischemic stroke were eligible for the study.
Exclusion Criteria
Patients with cardioembolic stroke, transient ischemic attacks (TIA), large infarcts requiring intracranial pressure control, severe strokes (e.g. basilar occlusion), internal bleeding, or strokes requiring thrombolytic therapy were excluded from the study.
Patient Involvement:
Eligible patients received a complete diagnostic workup for stroke, including MRI and MRA, and were randomized into either a heparin-treatment group or an aspirin-treatment group. The heparin group received intravenous heparin, titrated according to activated partial thromboplastin time (aPTT) for 6 days. At that point, the heparin was discontinued, and the patients received aspirin 300 mg/day for the rest of the study. Patients in the aspirin group received aspirin 300 mg/day throughout the study period. All patients had their NIHSS score evaluated daily for 1 week, and again at 2 weeks. MRS and BI scores were assessed at 1 and 3 months.
Primary Outcome:
National Institute of Health Stroke Scale (NIHSS) score at 1 week, relative to baseline NIHSS score.
Secondary Outcome:
Barthel Index (BI) and Modified Rankin Scale (MRS) at 3 months.
Source of Information:
Presented at the 25th International Stroke Conference (February 2000). Presented at the 4th World Stroke Congress 11/00.
|
|
Web Links and Publications:
|
|
This information last updated on: 7/16/2008
Reviewed on: 05/07/2009.
|
Trials
Directories